BDSX

BIODESIX INC
—

Company Information

Company Name
BIODESIX INC
CIK
CIK0001439725
Category
Non-accelerated filer<br>Smaller reporting company
Ticker: Exchange
BDSX: Nasdaq
Fiscal Year End
December 31
Owner Organization
08 Industrial Applications and Services
SIC
8071
SIC Description
Services-Medical Laboratories
Ticker
BDSX

SEC filing data through

Insider Sentiment

Last purchase
2026-08-12
Last sale
2026-02-23
Shares purchased (TTM)
3,764,638
Shares sold (TTM)
17,205
Buy ratio (TTM)99.5%

Institutional Sentiment

As of
2026-06-30
Institutional shares owned
4,035,321
Shares outstanding
10,296,000
Ownership
39.19%

Earnings Market Reaction

Filing date
2026-11-05
Price on filing date
—
1-month reaction
Pending
3-month reaction
Pending
Drift continued5/11 (45%)
Faded / reversed6/11 (55%)

Balance Sheet

Values in millions ($)
Line item2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-312023-12-31Subscriber-only columnSubscriber-only columnSubscriber-only columnSubscriber-only columnSubscriber-only columnTrend
Assets Current
Cash And Cash Equivalents At Carrying Value283026191721182631421126
Accounts Receivable Net Current9910913789810108
Other Assets Current546444455576
Assets Current424441333332303944582840
Assets Noncurrent
Property Plant And Equipment Net242424252526272829282928
Intangible Assets Net Excluding Goodwill333445566778
Operating Lease Right Of Use Asset443332222222
Goodwill151515151515151515151515
Other Assets Noncurrent668887777767
Assets Noncurrent525254555555575859585959
Assets94959587898886971031168799
Liabilities Current
Accounts Payable Current324343323233
Accrued Liabilities Current91081110107109888
Contract With Customer Liability Current000131111000
Operating Lease Liability Current221111111000
Business Combination Contingent Consideration Liability Current---------61922
Notes Payable To Bank Current-00000000000
Other Liabilities Current111111111000
Liabilities Current141514171815131413183133
Liabilities Noncurrent
Long Term Notes Payable474746474747373636363635
Operating Lease Liability Noncurrent232324242424242525252525
Other Liabilities Noncurrent111111111111
Liabilities Noncurrent717171737271626262626161
Liabilities858686909087757675809395
Stockholders Equity
Common Stock Value000000000000
Additional Paid In Capital530522515495492486485483482480428424
Retained Earnings Accumulated Deficit-521-513-506-498-494-485-474-462-454-444-433-420
Stockholders Equity999-2-2111212836-65
Liabilities And Stockholders Equity94959587898886971031168799
Allowance For Doubtful Accounts Receivable000000000000
Preferred Stock Par Or Stated Value Per Share0.000.000.000.000.000.000.000.000.000.000.000.00
Preferred Stock Shares Authorized555555555555
Preferred Stock Shares Issued000000000000
Preferred Stock Shares Outstanding000000000000
Common Stock Par Or Stated Value Per Share0.000.000.000.000.000.000.000.000.000.000.000.00
Common Stock Shares Authorized200200200200200200200200200200200200
Common Stock Shares Issued111110887777755
Shares Outstanding111110887777755
Stockholders Equity Note Stock Split Conversion Ratio1----0-------

Select a line item above to chart it.

Recent filings

Financial statements beyond 3 years are for subscribers only.

Unlock 17+ years of income statements, balance sheets, and cash flow statements

Start 7-day free trial

BIODESIX INC (BDSX) — SEC Financial Statements & Analysis

BIODESIX INC (BDSX) is a services-medical laboratories company, incorporated in DE. BIODESIX INC trades on Nasdaq as: BDSX. BIODESIX INC (BDSX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-09-30, filed with the SEC on 2026-11-05. Based on that filing, BIODESIX INC carries a market cap of $317.99M, a P/E ratio of -11.74x, a P/B ratio of 36.66x, a P/S ratio of 3.02x, an enterprise value of $336.64M, and an EV/EBITDA multiple of -23.88x. On profitability, it posts a gross margin of 115.07%, an operating margin of -18.69%, a net margin of -25.74%, a Return on Equity (ROE) of -778.89%, a Return on Assets (ROA) of -29.65%, and a Return on Invested Capital (ROIC) of -65.86%. Per share, it reports EPS of $-2.54, diluted EPS of $-2.54, free cash flow per share of $-1.79, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 31.23% year-over-year, net income growth of -31.51% year-over-year, and EPS growth of -51.81% year-over-year. On the balance sheet, it maintains a current ratio of 2.96x, a quick ratio of 2.96x, working capital of $27.89M, a debt-to-equity ratio of 9.83x, a debt ratio of 0.91, an interest coverage ratio of -2.45x, free cash flow of $-19.07M (TTM), and net debt of $18.65M. Figures sourced from SEC EDGAR.

Market Cap
$317.99M
P/E TTM
-11.74x
EPS TTM
$-2.54
P/B TTM
36.66x
ROE TTM
-778.89%
ROA TTM
-29.65%
Debt To Equity
9.83x
Free Cash Flow TTM
$-19.07M
Net Revenue TTM Growth 1Y
31.23%

Data as of 2026-09-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is BIODESIX INC in?

BIODESIX INC (BDSX) operates in the Services-Medical Laboratories industry.

What exchange does BDSX trade on?

BIODESIX INC (BDSX) trades on the Nasdaq.

Where is BIODESIX INC incorporated?

BIODESIX INC is incorporated in DE.

When was BIODESIX INC (BDSX)'s most recent SEC filing?

BIODESIX INC (BDSX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-09-30, filed with the SEC on 2026-11-05.

What is BDSX's market cap?

BIODESIX INC (BDSX) has a market capitalization of $317.99M as of 2026-09-30.

What is BDSX's EPS (earnings per share)?

BIODESIX INC (BDSX)'s trailing twelve month EPS is $-2.54 as of 2026-09-30.

What is BDSX's ROE (return on equity)?

BIODESIX INC (BDSX)'s trailing twelve month Return on Equity (ROE) is -778.89% as of 2026-09-30.

What is BDSX's ROA (return on assets)?

BIODESIX INC (BDSX)'s trailing twelve month Return on Assets (ROA) is -29.65% as of 2026-09-30.

What is BDSX's ROIC (return on invested capital)?

BIODESIX INC (BDSX)'s trailing twelve month Return on Invested Capital (ROIC) is -65.86% as of 2026-09-30.

What is BDSX's EV/EBITDA?

BIODESIX INC (BDSX)'s trailing twelve month EV/EBITDA is -23.88x as of 2026-09-30.

Wall Street's data.
Main Street's price.